Back to top
more

Myriad Genetics (MYGN)

(Real Time Quote from BATS)

$25.19 USD

25.19
172,932

+0.26 (1.04%)

Updated May 14, 2024 11:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions

by Zacks Equity Research

AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.

Tirthankar Chakraborty headshot

U.S. Political Tumult Shrouds Markets: 5 Safe Picks

by Tirthankar Chakraborty

Trump's continuous bashing of the Fed and Treasury Secretary Steven Mnuchin's phone calls to major banks to assess their financial health have been unnerving investors.

Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

by Zacks Equity Research

Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) see strong testing volumes from new products.

Myriad Genetics Announces Encouraging EndoPredict Test Data

by Zacks Equity Research

Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.

Myriad (MYGN) Down 3.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

4 Quality Stocks to Counter Market Volatility

by Zacks Equity Research

With the markets currently facing a lot of gyration, investing in quality stocks seems prudent. After all, these stocks provide excellent risk-adjusted returns.

Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag

by Zacks Equity Research

Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.

Myriad Genetics (MYGN) Beats Q1 Earnings Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 43.33% and -0.80%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)

by Zacks Equity Research

Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.

What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.

Myriad Genetics (MYGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?

by Zacks Equity Research

Improvement in prescriptions growth rate of SUBSYS and SYNDROS to drive INSYS Therapeutics' (INSY) Q3 earnings.

What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?

by Zacks Equity Research

Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.

What's in Store for Zimmer Biomet (ZBH) This Earnings Season?

by Zacks Equity Research

Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.

Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.

Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?

by Zacks Equity Research

Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.

Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.

Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?

by Zacks Equity Research

Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.

Company News For Oct 11, 2018

by Zacks Equity Research

Companies in the news are: CPB, FAST, MYGN, PFE and SHLD

Sweta Jaiswal headshot

Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

by Sweta Jaiswal

Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.

Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Company News For Aug 23, 2018

    by Zacks Equity Research

    Companies In The News are: TGT,LOW,NAVG,HIG,MYGN

      Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

      by Zacks Equity Research

      Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.